Melatonin

Melatonin, or N-acetyl-5-methoxytryptamine, is an indolamine hormone primarily produced by the pineal gland and synthesized locally in the retina, following a circadian rhythm with elevated levels at night. Researchers primarily study melatonin for its roles in regulating sleep, circadian rhythms, and its antioxidant and anti-inflammatory properties, particularly during pregnancy. Key findings indicate that melatonin acts as a crucial antioxidant in the placenta, reducing oxidative stress and maintaining immune homeostasis, while also showing promise in improving sleep quality and synchronizing circadian rhythms. Additionally, studies suggest that melatonin's interaction with specific receptors (MT1 and MT2) may offer therapeutic avenues for various sleep disorders and mood-related conditions. Current research continues to explore melatonin's multifaceted roles and potential clinical applications, highlighting its significance in both physiological and therapeutic contexts.

Melatonin, also known as N-acetyl-5-methoxytryptamine or Circadin, is an endogenous hormone primarily produced by the pineal gland and also synthesized locally in the retina. It belongs to the class of indolamine hormones. Melatonin is synthesized from the amino acid tryptophan via the intermediate 5-hydroxytryptophan (5-HTP) and serotonin. It is released in a circadian rhythm, with levels peaking during the night. Researchers have observed that melatonin plays crucial roles in regulating sleep and circadian rhythms, acting as an antioxidant and anti-inflammatory agent, particularly in the placenta during pregnancy. It is involved in maintaining immune homeostasis and reducing oxidative stress, which is vital for a stable gestational environment. The primary mechanism of action for melatonin involves binding to high-affinity G protein-coupled receptors, MT1 and MT2. Activation of these receptors influences sleep regulation, circadian rhythms, mood disorders, and neuroprotection. Melatonin's pharmacological properties have led to the development of slow-release formulations like Circadin and synthetic agonists for therapeutic use. Pharmacokinetically, melatonin has a short half-life, with oral bioavailability being limited due to first-pass metabolism. Researchers have found that it is well-tolerated with no significant short- or long-term adverse effects. Clinically, melatonin is used as an alternative treatment for sleep disorders, offering fewer side effects compared to traditional pharmaceuticals. It is available over-the-counter in many regions, though regulatory status varies globally.

Melatonin acts primarily through MT1 and MT2 receptors, which are G protein-coupled receptors. Activation of these receptors modulates various biological processes, including sleep and circadian rhythm regulation, mood stabilization, and neuroprotection.

Melatonin primarily exerts its effects through the activation of two high-affinity G protein-coupled receptors, MT1 and MT2, which are involved in various signaling pathways, including the inhibition of adenylate cyclase and modulation of intracellular calcium levels. This receptor activation influences biological processes such as circadian rhythm regulation, sleep onset, and antioxidant defense mechanisms, particularly in the placenta where it reduces oxidative stress and inflammation. Although the precise mechanisms of action are still being elucidated, melatonin's role in regulating the growth hormone/IGF-1 axis and immune homeostasis during pregnancy highlights its multifaceted biological significance.

Current evidence is limited regarding the long-term effects of melatonin supplementation on sleep disorders, particularly in diverse populations, including children and the elderly. Further research is needed to clarify the specific mechanisms through which melatonin receptors MT1 and MT2 mediate various therapeutic effects, as well as to explore the potential interactions between melatonin and other hormones in the growth hormone/IGF-1 axis across different demographics. Additionally, larger randomized controlled trials are necessary to resolve contradictory findings related to melatonin's impact on immune modulation during pregnancy and its efficacy compared to traditional sleep medications.